European Journal of Biomedical and Pharmaceutical Sciences

A COMPARATIVE EVALUATION OF QUALITY OF LIFE OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND ACUTE MYELOID LEUKEMIA IN CORRELATION WITH THE TREATMENT REGIMEN- A PROSPECTIVE, OBSERVATIONAL, COHORT STUDY

Syed Jaffer*, Faizan Hussaini, Niloufer Khadija, Syed Muneb Ahmed, Hafsa Navera, Anudeep Padakanti, Anupama Koneru

ABSTRACT

Aim: The aim of this study is to comparatively evaluate the Quality of Life of Patients with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia in Correlation with the Treatment Regimen. Objectives: To evaluate Comparative assessment of the computed health-related life quality (HRQoL) of patients and determination of which patients have a superior quality of life. Comparative evaluation of the adverse drug events in both the groups and determining which group observes a higher frequency of said adverse drug event. Methodology: This Prospective, Observational, Cohort Study was performed in department of oncology in MNJ Institute of Oncology & Regional Cancer Centre, Red Hills, Hyderabad.over a period of 5months.The quality of life and adverse medication events in health- related groups were researched and comparative assessments were conducted to identify which patient group had a better quality of life. Descriptive and inferential statistics were used for data analysis. The means were calculated and compared for physical, emotional, social, and functional health domains for patient with ALL and AML. Results: At a total of 120 patients divided into two subgroup ALL(60) and AML(60).The present study showed that the mean overall health-related Quality of Life score was 92.50±15.22 in ALL patients and 94.67±16.05 in AML patients. 55% of ALL patients suffered a poorer quality of life compared to the mean score. In the AML cohort, 43% of patients had a worse quality of life.In terms of adverse reactions, there was a significant difference between groups in nausea (p-value = 0.0340), pain (p-value = 0.0044), dyspnea (p-value = 0.0001), and insomia (p- value = 0.0344).In addition, there was no statistically significant difference in other adverse events such as fatigue (p=0.0379), loss of appetite (p=0.3154), or proportion of diarrhoea (p=0.5293). Conclusion: The mean total score between acute lymphoblastic leukemia and acute myeloid leukemia was determined to have no significant statistical difference. Although of not much significance, the median overall health score AML's life quality was better than ALL's.Extensive research needs to be carried out for the discovery of more efficient chemical molecules to target the cancer cells with better accuracy and reduce adverse drug events.

Keywords: ALL, AML, Cancer, HrQoL, Leukemia, FACT Leu.